.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Healthtrust
Dow
McKesson
Mallinckrodt
Teva
Moodys
Colorcon
QuintilesIMS
Harvard Business School

Generated: June 27, 2017

DrugPatentWatch Database Preview

WELLBUTRIN Drug Profile

« Back to Dashboard

What is the patent landscape for Wellbutrin, and what generic Wellbutrin alternatives are available?

Wellbutrin is a drug marketed by Glaxosmithkline and Valeant Intl and is included in three NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in WELLBUTRIN is bupropion hydrochloride. There are thirty-six drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.

Summary for Tradename: WELLBUTRIN

Patents:0
Applicants:2
NDAs:3
Bulk Api Vendors: see list116
Clinical Trials: see list62
Patent Applications: see list752
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:WELLBUTRIN at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
WELLBUTRIN
bupropion hydrochloride
TABLET;ORAL018644-001Dec 30, 1985DISCNNoNo► Subscribe► Subscribe
Glaxosmithkline
WELLBUTRIN SR
bupropion hydrochloride
TABLET, EXTENDED RELEASE;ORAL020358-004Jun 14, 2002AB1RXYesYes► Subscribe► Subscribe
Glaxosmithkline
WELLBUTRIN SR
bupropion hydrochloride
TABLET, EXTENDED RELEASE;ORAL020358-001Oct 4, 1996DISCNNoNo► Subscribe► Subscribe
Valeant Intl
WELLBUTRIN XL
bupropion hydrochloride
TABLET, EXTENDED RELEASE;ORAL021515-001Aug 28, 2003AB3RXYesNo6,096,341► Subscribe ► Subscribe
Glaxosmithkline
WELLBUTRIN
bupropion hydrochloride
TABLET;ORAL018644-002Dec 30, 1985DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: WELLBUTRIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
WELLBUTRIN
bupropion hydrochloride
TABLET;ORAL018644-002Dec 30, 19854,393,078► Subscribe
Glaxosmithkline
WELLBUTRIN
bupropion hydrochloride
TABLET;ORAL018644-002Dec 30, 19854,425,363► Subscribe
Glaxosmithkline
WELLBUTRIN
bupropion hydrochloride
TABLET;ORAL018644-003Dec 30, 19854,425,363► Subscribe
Glaxosmithkline
WELLBUTRIN
bupropion hydrochloride
TABLET;ORAL018644-001Dec 30, 19854,347,257► Subscribe
Glaxosmithkline
WELLBUTRIN
bupropion hydrochloride
TABLET;ORAL018644-002Dec 30, 19853,885,046► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: WELLBUTRIN

Drugname Dosage Strength RLD Submissiondate
bupropion hydrochlorideExtended-release Tablets150 mg and 300 mgWellbutrin XL9/21/2004
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Chinese Patent Office
McKinsey
Medtronic
McKesson
Accenture
Cerilliant
Farmers Insurance
Daiichi Sankyo
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot